Andrew Lees

CEO and Owner

Dr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, holds over 20 patents and is the author or co-author of more than 60 peer-reviewed papers. He holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Biophysics from The Johns Hopkins University. GlaxoSmithKline, the Serum Institute of India, the Chengdu Institute of Biological Products, and others all use conjugation chemistry (CDAP) developed by Dr. Lees in their S. pneumonia and meningococcal conjugate vaccines.

Dr. Lees is also an associate professor at the University of Maryland School of Medicine’s Center for Vaccine Development, an affiliate at the University of Maryland Bioprocessing Scale-Up Facility, and an adjunct professor in the Department of Medicine at the Uniformed Services University. He teaches protein chromatography through the post-graduate level, and is a frequent speaker on conjugation chemistry and biotech entrepreneurship.

Talks About
#crm197 #finabio #vaccines

Preferred Locations
#NorthAmerica